IMC Chicago
TRVI icon

IMC Chicago’s Trevi Therapeutics TRVI Stock Holding History

IMC Chicago’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,400
Closed -$315K – 6803
2026
Q1 		$315K Sell
26,400
-4,500
-15% -$50.4K ﹤0.01% 4540
2025
Q4 		$387K Sell
30,900
-2,500
-7% -$28.9K ﹤0.01% 3642
2025
Q3 		$306K Buy
+33,400
New +$250K ﹤0.01% 3406

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

IMC Chicago's TRVI Position: Q2 2026 in Review

IMC Chicago sold out of Trevi Therapeutics (TRVI) in Q2 2026, closing a stake of 24,324 shares — an estimated $354K sold.

IMC Chicago first reported a position in TRVI in Q3 2025 and held it in 3 quarters. The position peaked at $486K in Q4 2025. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • IMC Chicago reported no remaining Trevi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • IMC Chicago sold 24,324 Trevi Therapeutics shares in Q2 2026, an estimated $354K.
  • IMC Chicago first reported a position in Trevi Therapeutics in Q3 2025 and held it in 3 quarters.
  • IMC Chicago's Trevi Therapeutics position peaked at $486K in Q4 2025.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.